Combined Oral Contraceptives

Composition and Formulations

• Combined oral contraceptives (COCs) contain both a progestin and an estrogen component, with the estrogen component typically being ethinyl estradiol (EE) in doses ranging from 10-50 μg, as recommended by the American Academy of Pediatrics 1
• Many providers begin with a COC containing 30-35 μg of ethinyl estradiol and a progestin such as levonorgestrel or norgestimate, according to the American Academy of Pediatrics 1
• Progestins in COCs are categorized by generations, including first-generation (norethindrone, ethynodiol diacetate), second-generation (levonorgestrel, norgestrel), third-generation (norgestimate, desogestrel), and fourth-generation (drospirenone, dienogest) progestins, as classified by the Journal of the American Academy of Dermatology 2

Effectiveness and Usage

• The American Academy of Pediatrics recommends that COCs can be started on the same day as the visit ("quick start") in healthy, nonpregnant individuals, with a backup method used for at least the first 7 days for contraceptive efficacy 1
• The Centers for Disease Control and Prevention (CDC) recommends prescribing up to 1 year of COCs at a time, as stated by the American Academy of Pediatrics 1

Safety Considerations

• The American Academy of Pediatrics notes that the most serious adverse event associated with COC use is the increased risk of blood clots, which increases from 1 per 10,000 to 3-4 per 10,000 woman-years during COC use 1
• The American Heart Association recommends that lower doses of ethinyl estradiol are recommended to minimize potential increased stroke risk, as published in the journal Stroke 3
• COCs should not be prescribed for patients with severe and uncontrolled hypertension, ongoing hepatic dysfunction, complicated valvular heart disease, migraines with aura or focal neurologic symptoms, thromboembolism or thrombophilia, or complications of diabetes, according to the American Heart Association and the journal Hypertension 4

Non-Contraceptive Benefits

• The Journal of the American Academy of Dermatology states that COCs offer numerous health benefits beyond contraception, including treatment of acne through anti-androgenic properties 2

Clinical Pearls

• The American Heart Association recommends that for patients with specific stroke risk factors, progestin-only contraception or nonhormonal contraception may be more appropriate, as published in the journal Stroke 3
• The American Academy of Pediatrics notes that while smoking should be discouraged, it is not a contraindication to COC use in individuals younger than 35 years old 1
• The Journal of the American Academy of Dermatology states that the absolute risk of venous thromboembolism associated with COC use is small compared to the risk during pregnancy 2

Oral Combined Contraception Pills

Composition and Types of COCs

• The American Academy of Dermatology categorizes progestins in COCs by generations, including first-generation: norethindrone and ethynodiol diacetate, second-generation: levonorgestrel and norgestrel, third-generation: norgestimate and desogestrel, and fourth-generation: drospirenone and dienogest, for women using contraception 5

FDA-Approved COCs for Acne Treatment

• The American Academy of Dermatology recommends four specific COC formulations for treating acne in women who desire contraception: Norgestimate/ethinyl estradiol, Norethindrone acetate/ethinyl estradiol/ferrous fumarate, Drospirenone/ethinyl estradiol, and Drospirenone/ethinyl estradiol/levomefolate 5

Mechanism of Action

• COCs prevent pregnancy by inhibiting gonadotropin-releasing hormone, follicle-stimulating hormone, and luteinizing hormone, and also decrease ovarian androgen production, increase sex hormone-binding globulin, and reduce free testosterone, according to the American Academy of Dermatology 5

Drug Interactions

• The American Academy of Pediatrics notes that COCs may have reduced effectiveness when taken with certain medications, particularly some antiretroviral agents, such as ritonavir-boosted protease inhibitors, nevirapine, and efavirenz, which can reduce hormonal levels of COCs 6

Low-Dose Birth Control Pills

Composition and Types

• Standard pill packs include 28 pills total, with 21-24 hormone pills and 4-7 placebo (hormone-free) pills, as recommended by the American Academy of Pediatrics 7, 8
• COCs are available in fixed-dose monophasic regimens (same dose throughout) or phasic regimens (varying doses), according to the American Academy of Pediatrics 8

Common Formulations

• Many providers begin with a monophasic pill containing 30-35 μg of ethinyl estradiol and a progestin such as levonorgestrel or norgestimate, as suggested by the American Academy of Pediatrics 7, 8
• Newer formulations include drospirenone-containing pills, which have anti-mineralocorticoid effects that may help mitigate blood pressure increases, as reported in Hypertension 9

Effectiveness and Safety

• Low-dose COCs are highly effective when used correctly, with a typical-use failure rate of approximately 9%, according to the American Academy of Pediatrics 8
• The most serious adverse event associated with COC use is the increased risk of blood clots (venous thromboembolism), which increases from 1 per 10,000 to 3-4 per 10,000 woman-years during COC use, as reported by the American Academy of Pediatrics 8
• This risk is still significantly lower than the risk during pregnancy (10-20 per 10,000 woman-years), as noted by the American Academy of Pediatrics 8

Benefits Beyond Contraception

• Decreased menstrual cramping and blood loss can be achieved with low-dose COCs, as recommended by the American Academy of Pediatrics 7, 8
• Improvement in acne through anti-androgenic properties can be expected with low-dose COCs, according to the American Academy of Pediatrics 7
• Low-dose COCs are beneficial for medical conditions such as anemia, severe dysmenorrhea, endometriosis, abnormal uterine bleeding, and Von Willebrand and other bleeding disorders, as reported by the American Academy of Pediatrics 7, 8
• Extended or continuous cycle regimens can be useful for conditions exacerbated cyclically, such as migraines without aura, epilepsy, and irritable bowel syndrome, as suggested by the American Academy of Pediatrics 7, 8
• Long-term use (>3 years) of low-dose COCs provides significant protection against endometrial and ovarian cancers, according to the American Academy of Pediatrics 7, 8

Clinical Pearls

• COCs can be started on the same day as the visit ("quick start") in healthy, non-pregnant individuals, with a backup method used for at least the first 7 days, as recommended by the American Academy of Pediatrics 7, 8
• Among low-dose pills, there are no clear data suggesting one formulation is superior to another for most users, according to the American Academy of Pediatrics 7, 8

Potential Adverse Effects

• The most common adverse effect of extended-cycle regimens is unscheduled bleeding, as reported by the American Academy of Pediatrics 7, 8
• Other common transient adverse effects include headache and nausea, according to the American Academy of Pediatrics 10
• Weight gain and mood changes have not been reliably linked to COC use, as noted by the American Academy of Pediatrics 10

Low-Dose Combined Oral Contraceptives

Recommended Formulations

• The American Academy of Pediatrics recommends monophasic pills containing 30-35 μg ethinyl estradiol with levonorgestrel or norgestimate as first-line options due to their established safety profile and effectiveness 11
• Second-generation progestins like levonorgestrel demonstrate a safer coagulation profile compared to newer progestins 12
• Among low-dose pills, there are no clear data suggesting one formulation is superior to another for most users, so the lowest copay option on a patient's insurance formulary is often appropriate 13

Safety Considerations

• COCs containing 35 μg or more of ethinyl estradiol have been demonstrated to show statistically higher odds ratios for VTE than lower doses 12
• Second-generation progestins (like levonorgestrel) have a safer thrombotic risk profile compared to third and fourth-generation progestins 12, 14

Special Considerations

• For patients with hypertension concerns, newer formulations with drospirenone may help mitigate blood pressure increases due to their anti-mineralocorticoid effects 14

Drug Interactions

• Drug interactions can reduce COC effectiveness, particularly with certain antiretroviral agents, anticonvulsants, and antibiotics 11

Contraceptive Effectiveness and Safety of Low-Dose COCs

Contraceptive Effectiveness

• The Centers for Disease Control and Prevention recommends that strict adherence to a 20 mcg COC regimen is necessary, as seven consecutive days of pill-taking is necessary to reliably prevent ovulation 15
• Studies examining 20 mcg pills showed more follicular activity when pills were missed compared to 30 mcg formulations, highlighting the importance of adherence 15

Initiation Protocol

• The Centers for Disease Control and Prevention recommends using backup contraception for the first 7 days if starting a COC more than 5 days after menstrual bleeding began 16

Continuous Low-Dose Combined Oral Contraceptives for Endometriosis in Perimenopausal Women

Introduction to Continuous Use

• The American Academy of Pediatrics states that combined oral contraceptives are completely reversible and have no negative effect on long-term fertility, and are a safe option throughout a woman's reproductive years, providing strong support for extended use through perimenopause 17
• Combined oral contraceptives can be safely prescribed continuously throughout a woman's reproductive years until natural menopause, with no specific maximum duration limit established in guidelines for perimenopausal women with endometriosis 17

Evidence for Long-Term Continuous Use

• Long-term use of combined oral contraceptives for more than 3 years provides significant protection against endometrial and ovarian cancers, which is particularly relevant for women with endometriosis who have elevated cancer risks 17

Specific Considerations for Perimenopausal Women

• For perimenopausal women with endometriosis, continuous regimens are particularly appropriate as they provide superior symptom control and prevent disease progression 17

Monitoring Requirements During Long-Term Use

• Blood pressure monitoring is the primary safety requirement for women on long-term combined oral contraceptive therapy, and should be performed regularly throughout treatment 18
• Blood pressure measurements can be obtained in nonclinical settings to facilitate ongoing monitoring 18
• Weight changes should be assessed and discussed if patients express concerns about changes perceived to be associated with their contraceptive method 18

When to Discontinue or Transition

• Combined oral contraceptives should be continued until natural menopause is confirmed or until contraindications develop, rather than stopping at an arbitrary age 17
• Discontinue combined oral contraceptives if category 3 or 4 contraindications develop per U.S. Medical Eligibility Criteria, including uncontrolled hypertension, thromboembolism, migraines with aura, or complicated valvular heart disease 18

Common Pitfalls to Avoid

• Do not arbitrarily discontinue combined oral contraceptives at age 40 or 45 - the safety profile supports use throughout reproductive years in healthy, non-smoking women 17
• Ensure 7 consecutive days of hormone pills are maintained to reliably prevent ovulation, particularly important if any pill-free intervals are incorporated 18
• Unscheduled bleeding is the most common adverse effect of extended-cycle regimens but does not indicate treatment failure 17

Drug Interactions with Oral Contraceptives

Medications That Interact with Oral Contraceptives

• Rifampin and rifabutin are the only antimicrobials that significantly reduce combined oral contraceptive (COC) effectiveness and require alternative contraception or backup methods, as recommended by the Centers for Disease Control and Prevention (CDC) 19, 20
• Certain anticonvulsants (phenytoin, carbamazepine, barbiturates, primidone, topiramate, oxcarbazepine) reduce COC effectiveness through enzyme induction, according to the CDC 19, 20
• Griseofulvin lessens COC effectiveness, as reported in the Journal of the American Academy of Dermatology 21, 22

Medications That Do Not Interact with Oral Contraceptives

• Tetracycline-class antibiotics (doxycycline, minocycline) have not been shown to reduce COC effectiveness when taken concomitantly, as stated in the Journal of the American Academy of Dermatology 21, 22
• Broad-spectrum antibiotics do not affect contraceptive effectiveness, according to the CDC 19
• Antifungals show no clinically significant pharmacokinetic interactions, as reported by the CDC 19
• Antiparasitics show no clinically significant pharmacokinetic interactions, according to the CDC 19

Clinical Recommendations

• Women taking oral contraceptives can safely use ashwagandha without concern for reduced contraceptive efficacy or increased adverse effects, as there is no documented drug interaction between ashwagandha and oral contraceptives based on current medical evidence from the CDC and the Journal of the American Academy of Dermatology 19, 20, 21, 22
• The American College of Obstetricians and Gynecologists (ACOG) and the CDC recommend continuing standard contraceptive counseling about medications that DO interact (rifampin, certain anticonvulsants, some antiretrovirals) 19, 20
• No additional backup contraception is needed when starting ashwagandha, as stated by the CDC 19

Oral Contraceptives for Perimenopause Symptoms

Contraindications and Precautions

• The American College of Physicians recommends that combined oral contraceptives should not be prescribed in patients with severe uncontrolled hypertension (≥160/100 mm Hg), current or history of thromboembolism or thrombophilia, migraines with aura or focal neurologic symptoms, complicated valvular heart disease, or ongoing hepatic dysfunction 23

Initiation and Monitoring

• The Centers for Disease Control and Prevention recommends using backup contraception for the first 7 days if starting combined oral contraceptives more than 5 days after menstrual bleeding began 24

Guideline Recommendations

• The US Preventive Services Task Force guidelines do not apply to treatment of menopausal symptoms like hot flashes or vaginal dryness, and the evidence supports combined oral contraceptive use for symptom management in perimenopausal women, which is a distinct clinical scenario from postmenopausal hormone replacement therapy 23, 25, 26

Management of Early Bleeding Patterns and Monitoring in COCP Therapy for Menorrhagia

Expected Bleeding Course

• The CDC notes that irregular bleeding during the first 3–6 months of combined oral contraceptive use is common, generally benign, and typically improves with continued therapy. 27

Interpretation of Breakthrough Bleeding

• CDC guidance states that unscheduled spotting or bleeding in the initial 3–6 months should not be considered treatment failure; counseling patients about expected bleeding patterns reduces discontinuation rates. 28

Safety Monitoring

• CDC recommendations emphasize regular blood‑pressure monitoring as the primary safety requirement for women on long‑term combined oral contraceptive therapy. 29

Management of Persistent Bleeding

• The CDC advises a short course of NSAIDs (5–7 days) to treat unscheduled spotting, light bleeding, or heavy/prolonged bleeding that persists despite combined oral contraceptive use. 29
• If bleeding remains unacceptable, the CDC recommends counseling patients about alternative options—particularly the levonorgestrel‑releasing intrauterine system—and offering another suitable method. 29

Low‑Estrogen Combined Oral Contraceptives – Evidence‑Based Recommendations

Definitions of Dose Categories

• Low‑dose combined oral contraceptives are defined as containing ≤30 µg ethinyl estradiol. 30
• Moderate‑dose combined oral contraceptives contain >30 µg to ≤50 µg ethinyl estradiol. 30

Natural‑Estrogen Formulations

• Estradiol valerate + dienogest shows no significant blood‑pressure change after 6 months of use in women of reproductive age. 30
• Estetrol 15 mg + drospirenone 3 mg demonstrates no blood‑pressure change after 13 treatment cycles, with a hypertension incidence of ≈0.2 %. 30
• Natural‑estrogen COCs may have fewer adverse cardiovascular effects than synthetic ethinyl estradiol‑based pills, although larger comparative trials are still needed. 30

Blood‑Pressure Effects of Specific Progestins

• Drospirenone‑containing pills (15–30 µg ethinyl estradiol + 3 mg drospirenone) lower systolic blood pressure by 1–4 mm Hg after 6 months, likely via anti‑mineralocorticoid activity. 30
• Because of this antihypertensive effect, drospirenone‑containing formulations are especially suitable for individuals with borderline hypertension or BP concerns. 30
• Traditional low‑dose COCs that pair ≤30 µg ethinyl estradiol with first‑, second‑, or third‑generation progestins can elevate blood pressure, although the rise does not appear dose‑dependent within the low‑dose range. 30

Clinical Selection Guidance for Hypertension Concerns

• When hypertension or BP elevation is a primary concern, clinicians should prefer drospirenone‑containing COCs (15–30 µg ethinyl estradiol + 3 mg drospirenone). 30

Acne Treatment Efficacy of Dienogest

Evidence from Dermatology Guidelines

• The American Academy of Dermatology confirms that dienogest is included among the progestogens shown to be effective for the treatment of acne in controlled clinical trials, providing moderate‑strength evidence. 31, 32

Combined Oral Contraceptives and Mood in Young Women with Anxiety‑Depressive Disorders

Safety of Combined Oral Contraceptives Regarding Depression

• The CDC (Centers for Disease Control and Prevention) guidelines classify depression as Category 1 (no restrictions) for combined oral contraceptive (COC) use, stating that COC use does not increase depressive symptoms compared with baseline or with non‑users who have depression【33】.

Recommended Formulation for Mood Stability

• The CDC‑endorsed recommendation is to initiate a low‑dose (30–35 µg ethinyl estradiol) monofasic COC containing levonorgestrel or norgestimate as first‑line therapy for women with mood disorders, because this formulation has an established safety profile, a lower thrombotic risk, and no evidence of worsening depressive symptoms【33】.

Venlafaxine Tolerability in Adolescents

• The American Academy of Pediatrics notes that venlafaxine is one of the most poorly tolerated antidepressants in adolescents, with frequent adverse effects comparable to duloxetine and paroxetine【34】【35】.